Sumitomo Dainippon Pharma : ESG Meeting (Discussion with Investors)
December 08, 2021 at 07:52 am IST
Share
ESG Meeting (Discussion with Investors)
December 8, 2021
Sumitomo Dainippon Pharma Co., Ltd.
Disclaimer Regarding Forward-looking Statements
This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.
Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.
Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.
Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group holds approximately 54% of the outstanding shares of Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com/.
1
Today's Agenda
1.
Application for Selection of "Prime Market"/Complying with
the Revised Japan's Corporate Governance Code
Representative Director, President and CEO
Hiroshi Nomura
2.
Setting KPIs for Materiality/Initiatives for Environment
Executive Officer
Atsuko Higuchi
3.
Panel Discussion Panelists:
Member, Board of Directors, Chairman
Masayo Tada
Representative Director, President and CEO
Hiroshi Nomura
Representative Director, Executive Vice President
Toru Kimura
Member, Board of Directors (Outside)
Yutaka Atomi
Member, Board of Directors (Outside)
Saeko Arai
Member, Board of Directors (Outside)
Nobuhiro Endo
Member, Board of Directors (Outside)
Minoru Usui
Executive Officer
Atsuko Higuchi
Facilitator:
RIDEAL CEO
Mariko Mishiro
4. Q&As
2
Application for Selection of "Prime Market"/
Complying with the Revised Japan's Corporate Governance Code
Hiroshi Nomura
Representative Director, President and CEO
3
Application for Selection of "Prime Market"
Application for Selection of "Prime Market"
At a meeting of the Board of Directors (BoD) held on November 30, 2021, the Company's BoD resolved to select and apply for listing on the Prime Market, Tokyo Stock Exchange new market segments
Next step
We will make continued efforts to achieve the high-level governance required of companies listed on the Prime Market by complying with, for example, the revised Japan's Corporate Governance Code
We will work to achieve sustained growth and improve corporate value over the mid- to long-term through constructive dialogues with investors and other means
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sumitomo Dainippon Pharma Co. Ltd. published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 02:21:05 UTC.
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).